& Events
& Events
News
& Events
Oct 17, 2022 Inversago Pharma Raises $95 million CAD in Series C Financing
– Series C financing led by NEA – Provides advancement of INV-202 Phase 2 clinical trial in Diabetic Kidney Disease in Q4 MONTREAL (CANADA) – October 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C […]
Sep 29, 2022 Inversago Pharma Awarded the ʻPromising Health Biotech Company of the Yearʼ Gold Leaf Award at the BIONATION Conference in Ottawa
MONTREAL (CANADA) – September 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the ʻPromising Health Biotech Company of the Yearʼ Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada. An initiative of BIOTECanada, […]
Sep 15, 2022 Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
– FDA clears IND of First-In-Class, Peripherally-Acting CB1 Inverse Agonist INV-202 – Phase 2 trial in Diabetic Kidney Disease will also provide data in complications of diabetes, metabolic syndrome and dyslipidemia MONTREAL (CANADA) – September 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse […]
Sep 5, 2022 Inversago Pharma presents data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
MONTREAL (CANADA) – September 5, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), currently held in Barcelona, Spain and online. These data show that Inversago’s INV-101 (zevaquenabant), a […]
